Clinical trials
Musculoskeletal Diseases or Conditions clinical trials
Below are recruiting musculoskeletal diseases or conditions clinical trials, each written for real people, not researchers. We’re tracking 4,021 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04839757Recruiting
Testing a dengue vaccine plan for kids in the Caribbean
This trial looks at a dengue vaccine strategy in children ages 9 to 17 in Martinique and Guadeloupe. It may help protect kids from dengue, based on how the vaccine is accepted and how the study is carried out.
Fort-de-FranceAges 9–17 - NCT05709288RecruitingPhase 1
Gene therapy for teens with hemophilia B
This Phase 1 study tests a one-time gene therapy treatment (BBM-H901) for boys ages 12 to 18 with hemophilia B. It aims to see if the treatment is safe and can help the body make more clotting factor over time.
Tianjin, Tianjin MunicipalityAges 12–18 - NCT06238908RecruitingEarly Phase 1
Gene therapy NGGT003 for severe hemophilia A
This early-phase trial tests a new gene therapy called NGGT003 for men with severe hemophilia A. It aims to see if the treatment is safe and can help reduce bleeding episodes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04600960RecruitingPhase 2
Eltrombopag to raise low platelets after chemotherapy
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05236582RecruitingPhase 2
Herombopag for low platelets from chemotherapy side effects
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05641610RecruitingPhase 1/Phase 2
Study drug for adults with hemophilia B who still bleed
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05630651Recruiting
ZS801 for adults with severe hemophilia B
This trial studies ZS801, a gene therapy, in adults with hemophilia B who have very low natural FIX (a clotting protein) and frequent bleeding or joint problems. It aims to see how well it works and whether it is safe, especially by monitoring blood counts, infections, and immune responses.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05781100Recruiting
Study of baby behavior and family technology use
This study looks at how babies’ behavior relates to how families use technology. You may be able to take part if you’re in late pregnancy and can follow up over time after your baby is born.
San Luis Obispo, CaliforniaAges Any age - NCT06281327RecruitingPhase 2
Avatrombopag for children with ITP switching from eltrombopag
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
TianjinAges 6–18 - NCT06351839Recruiting
Sleep better despite long-term pain
This trial tests a program to help people with chronic pain and insomnia sleep better. It focuses on combining pain management with sleep improvement strategies.
Tromsø, Troms CountyAges 18–75 - NCT06094881RecruitingPhase 2
Obinutuzumab for teens with immune thrombocytopenia
This trial tests a drug called obinutuzumab for teens aged 12–18 with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if obinutuzumab can safely raise platelet counts in those who haven't responded well to steroids or other treatments.
TianjinAges 12–18 - NCT07372508Recruiting
Lung cancer screening with low-dose CT and AI in Glasgow
This study is testing whether a low-dose CT scan, analyzed with artificial intelligence, can help find lung cancer and other heart or lung conditions early. It may be a good fit if you are a current or former smoker in the Glasgow area and meet the age and smoking history requirements.
GlasgowAges 55–74 - NCT07376486Recruiting
Early treatment for type 2 diabetes using a new duodenal procedure
This study tests a new procedure called pulsENDO, which is done in the first part of the small intestine (the duodenum) to help treat type 2 diabetes. It may be an option for people who were recently diagnosed and have good blood sugar control with little or no diabetes medication.
ShatinAges 18–60 - NCT07378813Recruiting
Light vs. heavy weight training for Parkinson's disease
This study compares two types of weight training (lifting lighter weights versus heavier weights) in people with Parkinson's disease. It aims to see which approach best improves movement, strength, and daily function.
Coral Gables, FloridaAges 50–85 - NCT07374874Recruiting
Heart and nervous system health after stem cell transplant
This study looks at how your autonomic nervous system (the part that controls heartbeat and digestion) affects the risk of graft-versus-host disease (a condition where donor cells attack your body) after a half-matched stem cell transplant. You may be able to join if you are older than 16 and receiving a half-matched transplant from a family donor.
Tianjin, Tianjin MunicipalityAges 16 years+ - NCT07379216Recruiting
Vitamin C and glutathione drink for skin health
This study tests a liquid supplement containing vitamin C and glutathione to see if it benefits skin health. It may be a good fit if you are a healthy adult looking to improve your skin without using other skin products during the study.
Pingtung CityAges 18–65 - NCT07371468RecruitingPhase 1
Study of an experimental drug for lupus, rheumatoid arthritis, and related conditions
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
Buenos AiresAges 18–70 - NCT07379151Recruiting
Long-term protection from a meningococcal vaccine
This study checks whether the MenFive™ vaccine still protects against meningococcal disease more than five years after vaccination. It aims to see how long the immune response lasts.
BamakoAges 7–36 - NCT04271644RecruitingPhase 1/Phase 2
CAR-T treatment targeting BCMA for hard-to-treat myeloma
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
Kunming, YunnanAges 18–75 - NCT04776330RecruitingPhase 1/Phase 2
BCMA-targeted CAR-T for relapsed or refractory multiple myeloma
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
Kunming, YunnanAges 18–75 - NCT07362875Recruiting
Muscle imaging study for myotonic dystrophy
This study uses MRI scans to measure muscle changes in people with myotonic dystrophy (DM1 or DM2) and healthy volunteers. The goal is to find better ways to track the disease over time.
Winston-Salem, North CarolinaAges 18–65 - NCT07369765Recruiting
Balloon vs stent for blocked arteries
This trial compares two procedures to open completely blocked coronary arteries: a drug-coated balloon or a drug-eluting stent. It may help patients with a single, medium-length blockage in a large enough artery.
IstanbulAges Any age - NCT07362199RecruitingPhase 2
New combo treatment for chronic ITP
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07362238RecruitingPhase 2
Daratumumab vs Rituximab for pediatric ITP
This study compares daratumumab to rituximab for children with primary immune thrombocytopenia (ITP) that hasn't improved with steroids. The goal is to find a better treatment to raise platelet counts and reduce bleeding risk.
TianjinAges 6–18
Hear when a new Musculoskeletal Diseases or Conditions trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for musculoskeletal diseases or conditions?
- Yes. Clin2 currently lists 4,021 recruiting musculoskeletal diseases or conditions studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a musculoskeletal diseases or conditions trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a musculoskeletal diseases or conditions trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.